Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company that focuses on developing and marketing prescription medicines for people and animals. Its primary focus is on gastrointestinal distress, particularly chronic and debilitating diarrhea. Jaguar Health’s two main business segments are Human Health and Animal Health.

The company’s primary product for human health is Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS who are on antiretroviral therapy. Jaguar Health is also currently researching and developing Crofelemer, which is seen as having multiple potential follow-on indications, including cancer therapy-related diarrhea and orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders. Crofelemer is also being tested for use in short bowel syndrome with intestinal failure, supportive care for diarrhea relief in inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome, and idiopathic/functional diarrhea.

In the Animal Health business segment, Jaguar Health is developing Lechlemer, a second-generation anti-secretory agent for cholera, as well as Canalevia, an oral plant-based drug candidate for the treatment of chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs.

Jaguar Health was founded in 2013, and is currently headquartered in San Francisco, California. The company is under the leadership of CEO Lisa Conte and President Craig Lewis. In 2017, Jaguar Health was recognized as a Top 5 Global Life Sciences Technology Innovator by the 2017 Global Technology Innovation Awards by CBI Magazine. The company has also been awarded grants from the U.S. Department of Defense for its novel drug technologies for treating diarrhea. In 2019, Jaguar Health announced that its Mytesi product was awarded a CRADA (Cooperative Research and Development Agreement) with the Walter Reed Army Institute of Research (WRAIR).